Importance: Studies have found that patients at high cardiovascular risk often fail to receive evidence-based therapies in community practice. Objective: To evaluate whether a multifaceted quality improvement intervention can improve the prescription of evidence-based therapies. Design, Setting, and Participants: In this 2-arm cluster randomized clinical trial, patients with established atherothrombotic disease from 40 public and private outpatient clinics (clusters) in Brazil were studied. Patients were recruited from August 2016 to August 2017, with follow-up to August 2018. Data were analyzed in September 2018. Interventions: Case management, audit and feedback reports, and distribution of educational materials (to health care professionals and patients) vs routine practice. Main Outcomes and Measures: The primary end point was prescription of evidence-based therapies (ie, statins, antiplatelet therapy, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) using the all-or-none approach at 12 months after the intervention period in patients without contraindications. Results:Of the 1619 included patients, 1029 (63.6%) were male, 1327 (82.0%) had coronary artery disease (843 [52.1%] with prior acute myocardial infarction), 355 (21.9%) had prior ischemic stroke or transient ischemic attack, and 197 (12.2%) had peripheral vascular disease, and the mean (SD) age was 65.6 (10.5) years. Among randomized clusters, 30 (75%) were cardiology sites, 6 (15%) were primary care units, and 26 (65%) were teaching institutions. Among eligible patients, those in intervention clusters were more likely to receive a prescription of evidence-based therapies than those in control clusters (73.5% [515 of 701] vs 58.7% [493 of 840]; odds ratio, 2.30; 95% CI, 1.14-4.65). There were no differences between the intervention and control groups with regards to risk factor control (ie, hyperlipidemia, hypertension, or diabetes). Rates of education for smoking cessation were higher among current smokers in the intervention group than in the control group (51.9% [364 of 701] vs 18.2% [153 of 840]; odds ratio, 11.24; 95% CI, 2.20-57.43). The rate of cardiovascular mortality, acute myocardial infarction, and stroke was 2.6% for patients from intervention clusters and 3.4% for those in the control group (hazard ratio, 0.76; 95% CI, 0.43-1.34). Conclusions and Relevance: Among Brazilian patients at high cardiovascular risk, a quality improvement intervention resulted in improved prescription of evidence-based therapies. Trial Registration: ClinicalTrials.gov identifier: NCT02851732.
RCT Entities:
Importance: Studies have found that patients at high cardiovascular risk often fail to receive evidence-based therapies in community practice. Objective: To evaluate whether a multifaceted quality improvement intervention can improve the prescription of evidence-based therapies. Design, Setting, and Participants: In this 2-arm cluster randomized clinical trial, patients with established atherothrombotic disease from 40 public and private outpatient clinics (clusters) in Brazil were studied. Patients were recruited from August 2016 to August 2017, with follow-up to August 2018. Data were analyzed in September 2018. Interventions: Case management, audit and feedback reports, and distribution of educational materials (to health care professionals and patients) vs routine practice. Main Outcomes and Measures: The primary end point was prescription of evidence-based therapies (ie, statins, antiplatelet therapy, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) using the all-or-none approach at 12 months after the intervention period in patients without contraindications. Results: Of the 1619 included patients, 1029 (63.6%) were male, 1327 (82.0%) had coronary artery disease (843 [52.1%] with prior acute myocardial infarction), 355 (21.9%) had prior ischemic stroke or transient ischemic attack, and 197 (12.2%) had peripheral vascular disease, and the mean (SD) age was 65.6 (10.5) years. Among randomized clusters, 30 (75%) were cardiology sites, 6 (15%) were primary care units, and 26 (65%) were teaching institutions. Among eligible patients, those in intervention clusters were more likely to receive a prescription of evidence-based therapies than those in control clusters (73.5% [515 of 701] vs 58.7% [493 of 840]; odds ratio, 2.30; 95% CI, 1.14-4.65). There were no differences between the intervention and control groups with regards to risk factor control (ie, hyperlipidemia, hypertension, or diabetes). Rates of education for smoking cessation were higher among current smokers in the intervention group than in the control group (51.9% [364 of 701] vs 18.2% [153 of 840]; odds ratio, 11.24; 95% CI, 2.20-57.43). The rate of cardiovascular mortality, acute myocardial infarction, and stroke was 2.6% for patients from intervention clusters and 3.4% for those in the control group (hazard ratio, 0.76; 95% CI, 0.43-1.34). Conclusions and Relevance: Among Brazilian patients at high cardiovascular risk, a quality improvement intervention resulted in improved prescription of evidence-based therapies. Trial Registration: ClinicalTrials.gov identifier: NCT02851732.
Authors: David Peiris; Tim Usherwood; Kathryn Panaretto; Mark Harris; Jennifer Hunt; Julie Redfern; Nicholas Zwar; Stephen Colagiuri; Noel Hayman; Serigne Lo; Bindu Patel; Marilyn Lyford; Stephen MacMahon; Bruce Neal; David Sullivan; Alan Cass; Rod Jackson; Anushka Patel Journal: Circ Cardiovasc Qual Outcomes Date: 2015-01-13
Authors: C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes Journal: Lancet Date: 2005-09-27 Impact factor: 79.321
Authors: Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon Journal: N Engl J Med Date: 2008-08-27 Impact factor: 91.245
Authors: Donna R Shelley; Gbenga Ogedegbe; Sheila Anane; Winfred Y Wu; Keith Goldfeld; Heather T Gold; Sue Kaplan; Carolyn Berry Journal: Implement Sci Date: 2016-07-04 Impact factor: 7.327
Authors: Elisabeth B França; Valéria Maria de Azeredo Passos; Deborah Carvalho Malta; Bruce B Duncan; Antonio Luiz P Ribeiro; Mark D C Guimarães; Daisy M X Abreu; Ana Maria N Vasconcelos; Mariângela Carneiro; Renato Teixeira; Paulo Camargos; Ana Paula S Melo; Bernardo L Queiroz; Maria Inês Schmidt; Lenice Ishitani; Roberto Marini Ladeira; Otaliba L Morais-Neto; Maria Tereza Bustamante-Teixeira; Maximiliano R Guerra; Isabela Bensenor; Paulo Lotufo; Meghan Mooney; Mohsen Naghavi Journal: Popul Health Metr Date: 2017-11-22
Authors: Alexander K Rowe; Samantha Y Rowe; David H Peters; Kathleen A Holloway; John Chalker; Dennis Ross-Degnan Journal: Lancet Glob Health Date: 2018-10-08 Impact factor: 26.763
Authors: Pedro Gabriel Melo de Barros E Silva; Otavio Berwanger; Dalton Bertolim Precoma; Margaret Assad Cavalcante; José Fernando Vilela-Martin; Estêvão Lanna Figueiredo; Renato Delascio Lopes; Luiz Carlos Bodanese; Jorge Ilha Guimarães; Jadelson Pinheiro de Andrade; Angelo Amato Vincenzo de Paola; Marcus Vinicius Bolivar Malachias; Luiz Alberto Piva E Mattos; Fernando Bacal; Oscar Pereira Dutra Journal: Arq Bras Cardiol Date: 2021-01 Impact factor: 2.000
Authors: Kenneth Scott Brimble; Philip Boll; Allan K Grill; Amber Molnar; Danielle M Nash; Amit Garg; Ayub Akbari; Peter G Blake; David Perkins Journal: BMJ Open Date: 2020-02-16 Impact factor: 2.692